Dr. Mark George Outlines the Clinical Study Underlying BrainsWay Treatment of Smoking Addiction


Professor Mark George of the Medical University of South Carolina describes the clinical data behind BrainsWay’s FDA-clearance for short-term smoking cessation – most notably among the 168 study subjects who completed treatment, the continuous quit rate was 28.4% in the active group, compared with 11.7% in the sham group.  Dr. George also highlights the potential to expand Deep TMS technology to treat other forms of addiction.